STC2 and BIRC5 promote metastasis and progression in different types of cancer [e.g., head and neck squamous cell carcinoma (49), hepatocellular carcinoma (50), lung cancer (51), and ovarian tumor (52)] and were overexpressed in high-risk patients. Here, BIRC5 is linked to hepatocellular carcinoma.